UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

Breast cancer research and treatment, 2021-02, Vol.186 (1), p.219-227

2021

Link zum Volltext

Verfügbarkeit prüfen

Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis

European journal of clinical pharmacology, 2021-02, Vol.77 (2), p.233-239

2021

Link zum Volltext

Verfügbarkeit prüfen

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors

Frontiers in pharmacology, 2019-10, Vol.10, p.1235-1235

2019

Link zum Volltext

Verfügbarkeit prüfen

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

Targeted oncology, 2020-08, Vol.15 (4), p.449-466

2020

Link zum Volltext

Verfügbarkeit prüfen

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

Cardiovascular diabetology, 2021-02, Vol.20 (1), p.39-39, Article 39

2021

Link zum Volltext

Verfügbarkeit prüfen

Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis

European journal of clinical microbiology & infectious diseases, 2021-06, Vol.40 (6), p.1169-1176

2021

Link zum Volltext

Verfügbarkeit prüfen

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

Pharmaceuticals (Basel, Switzerland), 2021-07, Vol.14 (8), p.738

2021

Link zum Volltext

Verfügbarkeit prüfen

Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective

Current medicinal chemistry, 2014-02, Vol.21 (4), p.417

2014

Link zum Volltext

Verfügbarkeit prüfen

Drug-induced liver injury: Towards early prediction and risk stratification

World journal of hepatology, 2017-01, Vol.9 (1), p.30-37

2017

Link zum Volltext

Verfügbarkeit prüfen

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System

Cancers, 2021-04, Vol.13 (8), p.1758

2021

Link zum Volltext

Verfügbarkeit prüfen

Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe

PloS one, 2015-03, Vol.10 (3), p.e0119551

2015

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase ® Spontaneous Reporting System

Cancers, 2022-12, Vol.15 (1), p.173

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System

Frontiers in pharmacology, 2021-12, Vol.12, p.740707

2021

Link zum Volltext

Verfügbarkeit prüfen

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Targeted oncology, 2022, Vol.17 (1), p.43-51

2022

Link zum Volltext

Verfügbarkeit prüfen

Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology

World journal of gastroenterology : WJG, 2016-11, Vol.22 (41), p.9057-9068

2016

Link zum Volltext

Verfügbarkeit prüfen

Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database

Frontiers in pharmacology, 2024, Vol.15, p.1275814-1275814

2024

Link zum Volltext

Verfügbarkeit prüfen

Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System

Multiple sclerosis, 2019-10, Vol.25 (12), p.1633-1640

2019

Link zum Volltext

Verfügbarkeit prüfen

Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal

Pharmaceuticals (Basel, Switzerland), 2022-05, Vol.15 (5), p.645

2022

Link zum Volltext

Verfügbarkeit prüfen

Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system

Acta diabetologica, 2020, Vol.57 (1), p.71-80

2020

Link zum Volltext

Verfügbarkeit prüfen

Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study

BMC pharmacology & toxicology, 2019-11, Vol.20 (1), p.65-65, Article 65

2019

Link zum Volltext

Verfügbarkeit prüfen

The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

Cardiovascular diabetology, 2023-01, Vol.22 (1), p.16-10, Article 16

2023

Link zum Volltext

Verfügbarkeit prüfen

Assessing liver injury associated with antimycotics:Concise literature review and clues from data mining of the FAERS database

World journal of hepatology, 2014-08, Vol.6 (8), p.601-612

2014

Link zum Volltext

Verfügbarkeit prüfen

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System

Cancers, 2022-09, Vol.14 (19), p.4610

2022

Link zum Volltext

Verfügbarkeit prüfen

ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance

EClinicalMedicine, 2021-08, Vol.38, p.101027-101027, Article 101027

2021

Link zum Volltext

Verfügbarkeit prüfen

Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe

PloS one, 2013-11, Vol.8 (11), p.e81208

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 184

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(161)

Publikationsform

Sprache

Englisch
(183)
Italienisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(157)
Life Sciences & Biomedicine
(153)
Humans
(98)
Pharmacology & Pharmacy
(81)
Pharmacovigilance
(49)
Medicine
(44)
Medicine & Public Health
(43)
Pharmacology/toxicology
(33)
Toxicology
(32)
Drugs
(29)
Public, Environmental & Occupational Health
(26)
Drug Safety And Pharmacovigilance
(25)
Female
(20)
Male
(20)
General & Internal Medicine
(17)
Medicine, General & Internal
(17)
Adverse Drug Reaction Reporting Systems
(16)
Original Research Article
(16)
United States Food And Drug Administration
(16)
Risk Factors
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective

Drug-induced liver injury: Towards early prediction and risk stratification

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System

Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe

Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase ® Spontaneous Reporting System

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology

Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database

Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System

Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal

Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system

Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study

The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

Assessing liver injury associated with antimycotics:Concise literature review and clues from data mining of the FAERS database

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System

ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance

Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe

Suchergebnisse filtern